DWTX insider transaction filings
Dogwood Therapeutics, Inc. — 26 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-06-17. Screen DWTX transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-17 | 4 | Keefer David R — Director | Grant/award (A): 16,800 (derivative) @ $0 | EDGAR |
| 2026-06-17 | 4 | De La Rosa Abel — Director | Grant/award (A): 16,800 (derivative) @ $0 | EDGAR |
| 2026-06-17 | 4 | Whitley Richard James — Director | Grant/award (A): 16,800 (derivative) @ $0 | EDGAR |
| 2026-06-17 | 4 | Thomas John C — Director | Grant/award (A): 16,800 (derivative) @ $0 | EDGAR |
| 2026-03-06 | 4 | Duncan Gregory Scott — CHIEF EXECUTIVE OFFICER, Director | Grant/award (A): 330,000 (derivative) @ $0 | EDGAR |
| 2026-03-06 | 4 | Gendreau Roger Michael — CHIEF MEDICAL OFFICER | Grant/award (A): 82,500 (derivative) @ $0 | EDGAR |
| 2026-03-06 | 4 | Grosswald Ralph — SVP OF OPERATIONS | Grant/award (A): 82,500 (derivative) @ $0 | EDGAR |
| 2026-03-06 | 4 | Walsh Angela — Chief Financial Officer | Grant/award (A): 82,500 (derivative) @ $0 | EDGAR |
| 2025-12-05 | 4 | Duncan Gregory Scott — CHIEF EXECUTIVE OFFICER, Director | Grant/award (A): 460,000 (derivative) @ $0 | EDGAR |
| 2025-12-05 | 4 | Gendreau Roger Michael — CHIEF MEDICAL OFFICER | Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2025-12-05 | 4 | Grosswald Ralph — SVP OF OPERATIONS | Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2025-12-05 | 4 | Walsh Angela — Chief Financial Officer | Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2025-11-25 | 4 | Sealbond Ltd — Director, 10% owner Conjoint Inc. — Director, 10% owner CK Life Sciences Intl (Holdings) Inc — Director, 10% owner | Conversion (C): 21,610,950 · Conversion (C): 2,842,638 · Conversion (C): 2,161.09 (derivative) @ $0 · Conversion (C): 284.26 (derivative) @ $0 | EDGAR |
| 2025-07-01 | 4 | Gendreau Roger Michael — CHIEF MEDICAL OFFICER | Grant/award (A): 12,075 (derivative) @ $0 | EDGAR |
| 2025-07-01 | 4 | Grosswald Ralph — SVP OF OPERATIONS | Grant/award (A): 12,075 (derivative) @ $0 | EDGAR |
| 2025-07-01 | 4 | Duncan Gregory Scott — CHIEF EXECUTIVE OFFICER, Director | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2025-07-01 | 4 | Keefer David R — Director | Grant/award (A): 2,362 (derivative) @ $0 | EDGAR |
| 2025-07-01 | 4 | Walsh Angela — Chief Financial Officer | Grant/award (A): 12,075 (derivative) @ $0 | EDGAR |
| 2025-07-01 | 4 | De La Rosa Abel — Director | Grant/award (A): 2,362 (derivative) @ $0 | EDGAR |
| 2025-07-01 | 4 | Whitley Richard James — Director | Grant/award (A): 2,362 (derivative) @ $0 | EDGAR |
| 2025-07-01 | 4 | Thomas John C — Director | Grant/award (A): 2,362 (derivative) @ $0 | EDGAR |
| 2025-06-23 | 4 | Keefer David R — Director | Grant/award (A): 210 (derivative) @ $0 · Grant/award (A): 210 (derivative) @ $0 | EDGAR |
| 2025-06-23 | 4 | De La Rosa Abel — Director | Grant/award (A): 210 (derivative) @ $0 · Grant/award (A): 210 (derivative) @ $0 | EDGAR |
| 2025-06-23 | 4 | Whitley Richard James — Director | Grant/award (A): 210 (derivative) @ $0 · Grant/award (A): 210 (derivative) @ $0 | EDGAR |
| 2025-06-23 | 4 | Thomas John C — Director | Grant/award (A): 210 (derivative) @ $0 · Grant/award (A): 210 (derivative) @ $0 | EDGAR |
| 2025-03-17 | 4 | CK Life Sciences Intl (Holdings) Inc — Director, 10% owner | Grant/award (A): 284.26 (derivative) @ $7.01 | EDGAR |
Recent 8-K events — Dogwood Therapeutics, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-13 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-17 | 8-K | 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-14 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-26 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-18 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-12 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-20 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-13 | 8-K | 1.01 — Entry into a Material Definitive Agreement 1.02 — Termination of a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-28 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-21 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=DWTX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →